Dr. Gina L. Westhoff

Obstetrics and Gynecology
2121 Northeast 139th Street, Suite 120, 
Vancouver, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
2121 Northeast 139th Street, Suite 120, 
Vancouver, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Gina Westhoff is an Obstetrics and Gynecologist in Vancouver, Washington. Dr. Westhoff is rated as an Experienced provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. Her top areas of expertise are Ovarian Cancer, Malignant Mixed Mullerian Tumor, Endometrial Cancer, Bladder Reconstruction, and Hernia Surgery. Dr. Westhoff is currently accepting new patients.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in WA
Hospital Affiliations
Legacy Salmon Creek Medical Center
Legacy Good Samaritan Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

2121 Northeast 139th Street, Suite 120, Vancouver, WA 98686

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Enrollment Status: Recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure
Study Phase: Not Applicable
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
View 5 Less Clinical Trials

6 Total Publications

Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: July 11, 2017
Similar Doctors
Distinguished in Desmoplastic Small Round Cell Tumor
Dr. Elizabeth G. Munro
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Desmoplastic Small Round Cell Tumor
Dr. Elizabeth G. Munro
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

University Professional Services

3181 Sw Sam Jackson Park Rd, 
Portland, OR 
 (15.9 miles away)
503-494-8311
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Elizabeth Munro is a Gynecologic Oncologist and an Oncologist in Portland, Oregon. Dr. Munro is rated as a Distinguished provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. Her top areas of expertise are Cervical Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Hernia Surgery. Dr. Munro is currently accepting new patients.

Advanced in Desmoplastic Small Round Cell Tumor
Dr. Rodney S. Rushing
Oncology | Obstetrics and Gynecology
Advanced in Desmoplastic Small Round Cell Tumor
Dr. Rodney S. Rushing
Oncology | Obstetrics and Gynecology
210 Southeast 136th Avenue, 
Vancouver, WA 
 (8.3 miles away)
360-944-9889
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rodney Rushing is an Oncologist and an Obstetrics and Gynecologist in Vancouver, Washington. Dr. Rushing is rated as an Advanced provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. His top areas of expertise are Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, Ureteral Reconstruction, and Bladder Reconstruction. Dr. Rushing is currently accepting new patients.

Experienced in Desmoplastic Small Round Cell Tumor
Dr. William E. Winter
Obstetrics and Gynecology | Oncology
Experienced in Desmoplastic Small Round Cell Tumor
Dr. William E. Winter
Obstetrics and Gynecology | Oncology
12123 Southwest 69th Avenue, 
Tigard, OR 
 (20.9 miles away)
971-708-7600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Winter is an Oncologist and an Obstetrics and Gynecologist in Tigard, Oregon. Dr. Winter is rated as an Advanced provider by MediFind in the treatment of Desmoplastic Small Round Cell Tumor. His top areas of expertise are Endometrial Cancer, Lump in the Abdomen, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, and Bladder Reconstruction. Dr. Winter is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Westhoff's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 25 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile